DE133885C
(da)
|
|
|
|
|
US2878264A
(en)
*
|
|
1959-03-17 |
|
Substituted amino alcohols |
DE1144279B
(de)
*
|
1957-09-26 |
1963-02-28 |
Robins Co Inc A H |
Verfahren zur Herstellung von 3-Aryl-3-hydroxypyrrolidinen und deren Salzen
|
US3135766A
(en)
|
1961-10-03 |
1964-06-02 |
Mead Johnson & Co |
3-substituted-3-pyrrolidinols
|
US3484473A
(en)
|
1967-05-12 |
1969-12-16 |
Buckman Labor Inc |
Methylene bisesters of thiolsulfonic acids
|
DE1934150A1
(de)
|
1968-07-10 |
1970-01-15 |
Pennwalt Corp |
Neue 1-Alkanoyloxy-1,2,4,5-tetrahydro-3H,3-benzazepine
|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
US3745162A
(en)
*
|
1970-08-31 |
1973-07-10 |
Robins Co Inc A H |
1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides
|
GB1448437A
(en)
|
1973-02-24 |
1976-09-08 |
Beecham Group Ltd |
Diphenylpropylamines
|
US4022791A
(en)
*
|
1975-06-03 |
1977-05-10 |
Pfizer Inc. |
2-Aminomethyl-3,4-dihydronaphthalenes
|
GB1504424A
(en)
*
|
1975-08-09 |
1978-03-22 |
Beecham Group Ltd |
Isoquinoline-derived aminoethers
|
BR7807288A
(pt)
|
1977-11-08 |
1979-06-12 |
Genentech Inc |
Processo para sintese de polinucleotidos
|
DD133885B1
(de)
|
1978-01-04 |
1981-02-25 |
Hans Lehmann |
Mittel zur bekaempfung von phytopathogenen bakterien und pilzen
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
US4500707A
(en)
|
1980-02-29 |
1985-02-19 |
University Patents, Inc. |
Nucleosides useful in the preparation of polynucleotides
|
US5132418A
(en)
|
1980-02-29 |
1992-07-21 |
University Patents, Inc. |
Process for preparing polynucleotides
|
US4415732A
(en)
|
1981-03-27 |
1983-11-15 |
University Patents, Inc. |
Phosphoramidite compounds and processes
|
US4668777A
(en)
|
1981-03-27 |
1987-05-26 |
University Patents, Inc. |
Phosphoramidite nucleoside compounds
|
US4973679A
(en)
|
1981-03-27 |
1990-11-27 |
University Patents, Inc. |
Process for oligonucleo tide synthesis using phosphormidite intermediates
|
US4542142A
(en)
|
1982-11-22 |
1985-09-17 |
Roussel Uclaf |
Insecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain
|
DE3329892A1
(de)
|
1983-08-18 |
1985-03-07 |
Köster, Hubert, Prof. Dr., 2000 Hamburg |
Verfahren zur herstellung von oligonucleotiden
|
US5118800A
(en)
|
1983-12-20 |
1992-06-02 |
California Institute Of Technology |
Oligonucleotides possessing a primary amino group in the terminal nucleotide
|
US5643889A
(en)
|
1984-07-11 |
1997-07-01 |
Temple University-Of The Commonwealth System Of Pennsylvania |
Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
|
FR2567892B1
(fr)
|
1984-07-19 |
1989-02-17 |
Centre Nat Rech Scient |
Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
FR2576898B1
(fr)
|
1985-02-01 |
1988-01-08 |
Lafon Labor |
Derives de 3-phenyl-tetrahydropyridine, procede de preparation et utilisation en therapeutique
|
US4659774A
(en)
|
1985-11-01 |
1987-04-21 |
American Hoechst Corporation |
Support for solid-phase oligonucleotide synthesis
|
US4840956A
(en)
*
|
1986-02-18 |
1989-06-20 |
Warner-Lambert Company |
Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents
|
US4735949A
(en)
*
|
1986-02-18 |
1988-04-05 |
Warner-Lambert Company |
Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents
|
IL83663A0
(en)
|
1986-10-27 |
1988-01-31 |
Robins Co Inc A H |
Preparation of 3-pyrrolidinols
|
JP2828642B2
(ja)
|
1987-06-24 |
1998-11-25 |
ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン |
ヌクレオシド誘導体
|
US5200553A
(en)
|
1987-07-30 |
1993-04-06 |
Kupat Holim Health Insurance Institution Of The General Federation Of Labor |
Biologically active carboxylic acid esters
|
US4923901A
(en)
|
1987-09-04 |
1990-05-08 |
Millipore Corporation |
Membranes with bound oligonucleotides and peptides
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
US4943629A
(en)
|
1988-08-12 |
1990-07-24 |
American Cyanamid Company |
Antidiabetic alpha-substituted phosphonates
|
US4945158A
(en)
|
1988-08-12 |
1990-07-31 |
American Cyanamid Company |
Antidiabetic phosphonates
|
US5047524A
(en)
|
1988-12-21 |
1991-09-10 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
US5262530A
(en)
|
1988-12-21 |
1993-11-16 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
JP2794461B2
(ja)
|
1989-08-17 |
1998-09-03 |
有機合成薬品工業株式会社 |
ホスホアミダイト化合物及びそれを用いたオリゴリボヌクレオチドの固相合成法
|
US5141813A
(en)
|
1989-08-28 |
1992-08-25 |
Clontech Laboratories, Inc. |
Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
CA2029273A1
(en)
|
1989-12-04 |
1991-06-05 |
Christine L. Brakel |
Modified nucleotide compounds
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
CA2071897A1
(en)
*
|
1989-12-28 |
1991-06-29 |
Richard A. Glennon |
Sigma receptor ligands and the use thereof
|
US5620963A
(en)
|
1991-10-15 |
1997-04-15 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
|
US7101993B1
(en)
|
1990-01-11 |
2006-09-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides containing 2′-O-modified purines
|
US5646265A
(en)
|
1990-01-11 |
1997-07-08 |
Isis Pharmceuticals, Inc. |
Process for the preparation of 2'-O-alkyl purine phosphoramidites
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
US5852188A
(en)
|
1990-01-11 |
1998-12-22 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having chiral phosphorus linkages
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
KR927003044A
(ko)
|
1990-01-11 |
1992-12-17 |
크리스토퍼 케이. 미라벨리 |
Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법
|
US5212295A
(en)
|
1990-01-11 |
1993-05-18 |
Isis Pharmaceuticals |
Monomers for preparation of oligonucleotides having chiral phosphorus linkages
|
US5457191A
(en)
|
1990-01-11 |
1995-10-10 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
US5506212A
(en)
|
1990-01-11 |
1996-04-09 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides with substantially chirally pure phosphorothioate linkages
|
US5635488A
(en)
|
1991-10-15 |
1997-06-03 |
Isis Pharmaceuticals, Inc. |
Compounds having phosphorodithioate linkages of high chiral purity
|
US6339066B1
(en)
|
1990-01-11 |
2002-01-15 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
US5292875A
(en)
|
1990-04-20 |
1994-03-08 |
Lynx Therapeutics, Inc. |
Method of synthesizing sulfurized oligonucleotide analogs
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
EP0531447B1
(en)
|
1990-05-23 |
1999-11-10 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating rna activity through modification of the 5' cap structure of rna
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
US5834607A
(en)
|
1990-07-27 |
1998-11-10 |
Isis Pharmaceuticals, Inc. |
Amines and methods of making and using the same
|
US5677437A
(en)
|
1990-07-27 |
1997-10-14 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US6087482A
(en)
|
1990-07-27 |
2000-07-11 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US5618704A
(en)
|
1990-07-27 |
1997-04-08 |
Isis Pharmacueticals, Inc. |
Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
|
WO1994022886A1
(en)
|
1993-03-30 |
1994-10-13 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US5783682A
(en)
|
1990-07-27 |
1998-07-21 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide mimics having nitrogen-containing linkages
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
US5223618A
(en)
|
1990-08-13 |
1993-06-29 |
Isis Pharmaceuticals, Inc. |
4'-desmethyl nucleoside analog compounds
|
US5792844A
(en)
|
1990-07-27 |
1998-08-11 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent nitrogen atoms
|
US5541307A
(en)
|
1990-07-27 |
1996-07-30 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs and solid phase synthesis thereof
|
US5608046A
(en)
|
1990-07-27 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Conjugated 4'-desmethyl nucleoside analog compounds
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US5998603A
(en)
|
1994-09-29 |
1999-12-07 |
Isis Pharmaceuticals, Inc. |
4'-desmethyl nucleoside analogs, and oligomers thereof
|
US5378825A
(en)
|
1990-07-27 |
1995-01-03 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
BR9106702A
(pt)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals Inc |
Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
|
US6121433A
(en)
|
1990-07-27 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having nitrogen-containing linkages
|
US5386023A
(en)
|
1990-07-27 |
1995-01-31 |
Isis Pharmaceuticals |
Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
|
US5688941A
(en)
|
1990-07-27 |
1997-11-18 |
Isis Pharmaceuticals, Inc. |
Methods of making conjugated 4' desmethyl nucleoside analog compounds
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
US5512668A
(en)
|
1991-03-06 |
1996-04-30 |
Polish Academy Of Sciences |
Solid phase oligonucleotide synthesis using phospholane intermediates
|
US20020183502A1
(en)
|
1991-05-21 |
2002-12-05 |
Mesmaeker Alain De |
Backbone-modified oligonucleotide analogs and methods for using same
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
JPH04348077A
(ja)
|
1991-05-24 |
1992-12-03 |
Nec Corp |
薄膜トランジスタ
|
US6414112B1
(en)
|
1991-05-24 |
2002-07-02 |
Ole Buchardt |
Peptide nucleic acids having 2,6-diaminopurine nucleobases
|
AT405053B
(de)
|
1991-06-10 |
1999-05-25 |
Lucky Ltd |
Hepatitis-c-diagnosemittel und -impfstoffe
|
US5359052A
(en)
|
1991-08-05 |
1994-10-25 |
Polish Academy Of Sciences |
Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
|
US5646267A
(en)
|
1991-08-05 |
1997-07-08 |
Polish Academy Of Sciences |
Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
|
US6369209B1
(en)
|
1999-05-03 |
2002-04-09 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
US7119184B2
(en)
|
1991-08-12 |
2006-10-10 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
US5607923A
(en)
|
1991-10-15 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
US5654284A
(en)
|
1991-10-15 |
1997-08-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
|
US5599797A
(en)
|
1991-10-15 |
1997-02-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
JP2693643B2
(ja)
|
1991-10-15 |
1997-12-24 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
キラルリン結合を有するオリゴヌクレオチド
|
US5576302A
(en)
|
1991-10-15 |
1996-11-19 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
|
EP0538194B1
(de)
|
1991-10-17 |
1997-06-04 |
Novartis AG |
Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
US6235887B1
(en)
|
1991-11-26 |
2001-05-22 |
Isis Pharmaceuticals, Inc. |
Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
|
US5359044A
(en)
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
ATE204879T1
(de)
|
1991-12-24 |
2001-09-15 |
Isis Pharmaceuticals Inc |
Antisense oligonukleotide
|
GB9213601D0
(en)
|
1992-06-26 |
1992-08-12 |
Mastico Robert A |
Protein based delivery system
|
US7067497B2
(en)
|
1992-09-29 |
2006-06-27 |
Isis Pharmaceuticals, Inc. |
Modulation of telomere length by oligonucleotides having a G-core sequence
|
US6444656B1
(en)
|
1992-12-23 |
2002-09-03 |
Biochem Pharma, Inc. |
Antiviral phosphonate nucleotides
|
US6005107A
(en)
|
1992-12-23 |
1999-12-21 |
Biochem Pharma, Inc. |
Antiviral compounds
|
DE69400208T2
(de)
|
1993-01-25 |
1996-11-28 |
Hybridon Inc |
Olionukleotidalkylphosphonate und -phosphonothioate
|
JPH08508490A
(ja)
|
1993-03-31 |
1996-09-10 |
スターリング ウィンスロップ インコーポレイティド |
新規5’−置換ヌクレオシド及びそれから得られるオリゴマー
|
WO1994022888A1
(en)
|
1993-03-31 |
1994-10-13 |
Sterlingwinthrop Inc. |
Bifunctional nucleosides, oligomers thereof, and methods of making and using the same
|
US5955591A
(en)
|
1993-05-12 |
1999-09-21 |
Imbach; Jean-Louis |
Phosphotriester oligonucleotides, amidites and method of preparation
|
US6015886A
(en)
|
1993-05-24 |
2000-01-18 |
Chemgenes Corporation |
Oligonucleotide phosphate esters
|
DE69412704T2
(de)
|
1993-06-10 |
1999-02-04 |
Idemitsu Petrochemical Co., Ltd., Tokio/Tokyo |
Spritzgiessform
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
US5643989A
(en)
|
1993-10-29 |
1997-07-01 |
Azdel, Inc. |
Fiber reinforced functionalized polyolefin composites
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
DE4435728A1
(de)
|
1994-01-19 |
1995-07-20 |
Boehringer Mannheim Gmbh |
Biotinsilan-Verbindungen und diese Verbindungen enthaltende Bindematrix
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
CA2183431A1
(en)
|
1994-02-22 |
1995-08-24 |
Allan Svendsen |
A method of preparing a variant of a lipolytic enzyme
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
US5871966A
(en)
|
1994-05-11 |
1999-02-16 |
Novo Nordisk A/S |
Enzyme with endo-1,3(4)-β- Glucanase activity
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
HRP950288A2
(en)
|
1994-05-31 |
1997-08-31 |
Bayer Ag |
Oxalylamino-benzofuran- and benzothienyl-derivatives
|
DE69507197T2
(de)
|
1994-05-31 |
1999-05-27 |
Bayer Ag, 51373 Leverkusen |
Aminobenzofuryl- und -thienylderivate
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
ATE328890T1
(de)
|
1994-07-15 |
2006-06-15 |
Univ Iowa Res Found |
Immunomodulatorische oligonukleotide
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
CA2199464A1
(en)
|
1994-09-07 |
1996-03-14 |
Radhakrishnan Iyer |
Oligonucleotide prodrugs
|
US5681940A
(en)
|
1994-11-02 |
1997-10-28 |
Icn Pharmaceuticals |
Sugar modified nucleosides and oligonucleotides
|
WO1996019572A1
(en)
|
1994-12-22 |
1996-06-27 |
Hybridon, Inc. |
Synthesis of stereospecific oligonucleotide phosphorothioates
|
GB9501465D0
(en)
|
1995-01-25 |
1995-03-15 |
King S College London |
Nucleoside phosphorothioate derivatives,synthesis and use thereof
|
AU5359496A
(en)
|
1995-03-06 |
1996-09-23 |
Isis Pharmaceuticals, Inc. |
Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
|
US6166197A
(en)
|
1995-03-06 |
2000-12-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
|
DE69638104D1
(de)
|
1995-04-27 |
2010-02-11 |
Takara Bio Inc |
Für Lacto-N-biosidase kodierendes Gen
|
ES2220929T3
(es)
|
1995-05-11 |
2004-12-16 |
Applied Research Systems Ars Holding N.V. |
Inhibidor de la actividad il-6.
|
WO1996036627A1
(en)
|
1995-05-19 |
1996-11-21 |
Glycomed Incorporated |
Collection of activated glycoside compounds and their biological use
|
AU5871196A
(en)
|
1995-05-23 |
1996-12-24 |
Hybridon, Inc. |
Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
|
ES2151173T3
(es)
|
1995-05-23 |
2000-12-16 |
Hybridon Inc |
Nuevos sintones para la sintesis estereoselectiva de oligonucleotidos.
|
EP0831854A4
(en)
|
1995-06-06 |
2001-01-24 |
Isis Pharmaceuticals Inc |
OLIGONUCLEOTIDS WITH PHOSPHOROTHIOATE BINDINGS OF HIGH CHIRAL PURITY
|
US5932450A
(en)
|
1995-06-07 |
1999-08-03 |
Gen-Probe Incorporated |
Enzymatic synthesis of oligonucleotides using digestible templates
|
US5795765A
(en)
|
1995-06-29 |
1998-08-18 |
Takara Shuzo Co., Ltd. |
Gene encoding endoglycoceramidase
|
DE69636649T2
(de)
|
1995-06-29 |
2007-10-04 |
Takara Bio Inc., Otsu |
Für einen Endoglycoceramidase-Aktivator kodierendes Gen
|
US6017700A
(en)
|
1995-08-04 |
2000-01-25 |
Bayer Corporation |
Cationic oligonucleotides, and related methods of synthesis and use
|
US5936080A
(en)
|
1996-05-24 |
1999-08-10 |
Genta Incorporated |
Compositions and methods for the synthesis of organophosphorus derivatives
|
WO1997009443A1
(en)
|
1995-09-05 |
1997-03-13 |
Michigan State University |
PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
|
US5734041A
(en)
|
1995-10-20 |
1998-03-31 |
Mcgill University |
Preparation of chiral phosphorothioate oligomers
|
US6160109A
(en)
|
1995-10-20 |
2000-12-12 |
Isis Pharmaceuticals, Inc. |
Preparation of phosphorothioate and boranophosphate oligomers
|
US6476216B1
(en)
|
1995-10-20 |
2002-11-05 |
Mcgill University |
Preparation of phosphorothioate oligomers
|
US7018793B1
(en)
|
1995-12-07 |
2006-03-28 |
Diversa Corporation |
Combinatorial screening of mixed populations of organisms
|
US6214805B1
(en)
|
1996-02-15 |
2001-04-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
RNase L activators and antisense oligonucleotides effective to treat RSV infections
|
JP2000506384A
(ja)
|
1996-02-15 |
2000-05-30 |
ナショナル インスティチューツ オブ ヘルス |
RNase L アクチベーター及びRSV感染の治療に有効なアンチセンスオリゴヌクレオチド
|
GB9604669D0
(en)
|
1996-03-05 |
1996-05-01 |
Ciba Geigy Ag |
Chemical compounds
|
US5824669A
(en)
|
1996-03-22 |
1998-10-20 |
Nitromed, Inc. |
Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
|
AU3025597A
(en)
|
1996-05-10 |
1997-12-05 |
Novo Nordisk A/S |
Method of providing novel dna sequences
|
US5856465A
(en)
|
1996-05-24 |
1999-01-05 |
Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych |
Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
DE19622783A1
(de)
|
1996-06-07 |
1997-12-11 |
Hoechst Ag |
Isolierung der Biosynthesegene für Pseudo-Oligosaccharide aus Streptomyces glaucescens GLA.O und ihre Verwendung
|
CA2260749A1
(en)
|
1996-07-16 |
1998-01-22 |
Gen-Probe Incorporated |
Methods for detecting rna analytes using modified probes
|
AU717387B2
(en)
|
1996-07-24 |
2000-03-23 |
Rolf H. Berg |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
AU4156197A
(en)
|
1996-08-21 |
1998-03-06 |
Hybridon, Inc. |
Oligonucleotide prodrugs
|
US6056973A
(en)
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
GB9621522D0
(en)
|
1996-10-16 |
1996-12-04 |
Biocompatibles Ltd |
Synthesis of phosphorus compounds
|
US6639062B2
(en)
|
1997-02-14 |
2003-10-28 |
Isis Pharmaceuticals, Inc. |
Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
US6369237B1
(en)
|
1997-03-07 |
2002-04-09 |
President And Fellows Of Harvard College |
DNA glycosylase inhibitors, and uses related thereto
|
US6015887A
(en)
|
1997-04-11 |
2000-01-18 |
Isis Pharmaceuticals, Inc. |
Chiral peptide nucleic acids and methods for preparing same
|
US6468983B2
(en)
|
1997-04-21 |
2002-10-22 |
The Cleveland Clinic Foundation |
RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
|
PL184612B1
(pl)
|
1997-04-25 |
2002-11-29 |
Pan |
Sposób wytwarzania modyfikowanych P chiralnych analogów nukleotydów
|
CA2291839A1
(en)
|
1997-05-28 |
1998-12-03 |
Peter E. Nielsen |
Conjugated peptide nucleic acids having enhanced cellular uptake
|
EP0991635A1
(en)
|
1997-06-27 |
2000-04-12 |
The Procter & Gamble Company |
Pro-fragrance cyclic acetals
|
WO1999005160A2
(en)
|
1997-07-25 |
1999-02-04 |
Hybridon, Inc. |
Oligonuclotides having 3' terminal stereospecific phosphorothioates
|
GB9717158D0
(en)
|
1997-08-13 |
1997-10-22 |
King S College London |
Solution synthesis of oligonucleotides and their phosphorothioate analogues
|
US6383808B1
(en)
|
2000-09-11 |
2002-05-07 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of clusterin expression
|
US6767739B2
(en)
|
2001-07-30 |
2004-07-27 |
Isis Pharmaceuticals Inc. |
Antisense modulation of microsomal triglyceride transfer protein expression
|
US6750344B1
(en)
|
1997-09-05 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Amine compounds and combinatorial libraries comprising same
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
DE19741715A1
(de)
|
1997-09-22 |
1999-03-25 |
Hoechst Ag |
Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
|
US6232463B1
(en)
|
1997-10-09 |
2001-05-15 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
US6617438B1
(en)
|
1997-11-05 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Oligoribonucleotides with enzymatic activity
|
US6528640B1
(en)
|
1997-11-05 |
2003-03-04 |
Ribozyme Pharmaceuticals, Incorporated |
Synthetic ribonucleic acids with RNAse activity
|
US6080543A
(en)
|
1997-12-08 |
2000-06-27 |
E. & J. Gallo Winery |
Detection of fungal pathogens
|
US6582936B1
(en)
|
1997-12-12 |
2003-06-24 |
The Regents Of The University Of California |
Methods for making nucleic acids
|
US6248519B1
(en)
|
1998-03-11 |
2001-06-19 |
E & J Gallo Winery |
Detection of fermentation-related microorganisms
|
US7045610B2
(en)
|
1998-04-03 |
2006-05-16 |
Epoch Biosciences, Inc. |
Modified oligonucleotides for mismatch discrimination
|
CA2328602A1
(en)
|
1998-05-06 |
1999-11-11 |
University Of Iowa Research Foundation |
Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
|
IL139646A0
(en)
|
1998-05-14 |
2002-02-10 |
Coley Pharm Group Inc |
Methods for regulating hematopoiesis using cpg-oligonucleotides
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
CA2333854A1
(en)
|
1998-07-27 |
2000-02-10 |
University Of Iowa Research Foundation |
Stereoisomers of cpg oligonucleotides and related methods
|
ATE315405T1
(de)
|
1998-08-10 |
2006-02-15 |
Antigenics Inc |
Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
|
WO2000023444A1
(en)
|
1998-10-21 |
2000-04-27 |
Abbott Laboratories |
5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
|
US6995259B1
(en)
|
1998-10-23 |
2006-02-07 |
Sirna Therapeutics, Inc. |
Method for the chemical synthesis of oligonucleotides
|
US6451524B1
(en)
|
1998-11-25 |
2002-09-17 |
Isis Pharmaceuticals, Inc. |
Identification of disease predictive nucleic acids
|
AU1742600A
(en)
|
1998-11-25 |
2000-06-13 |
Isis Pharmaceuticals, Inc. |
Identification of disease predictive nucleic acids
|
DK1141335T3
(da)
|
1998-12-21 |
2009-11-09 |
Genencor Int |
Kemisk modificerede enzymer med multipelt ladede varianter
|
CA2359816C
(en)
|
1999-01-06 |
2010-08-03 |
Genenews Inc. |
Method for the detection of gene transcripts in blood and uses thereof
|
US6265172B1
(en)
|
1999-02-08 |
2001-07-24 |
University Of Kentucky |
Diagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases
|
US6121437A
(en)
|
1999-03-16 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Phosphate and thiophosphate protecting groups
|
US6506594B1
(en)
|
1999-03-19 |
2003-01-14 |
Cornell Res Foundation Inc |
Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
|
GB9907245D0
(en)
|
1999-03-29 |
1999-05-26 |
Goldsborough Andrew |
Cleavage of nucleic acids from solid supports
|
JP3072345B1
(ja)
|
1999-03-31 |
2000-07-31 |
農林水産省家畜衛生試験場長 |
豚丹毒菌の組換えサブユニットワクチン
|
US5998148A
(en)
|
1999-04-08 |
1999-12-07 |
Isis Pharmaceuticals Inc. |
Antisense modulation of microtubule-associated protein 4 expression
|
US6977245B2
(en)
|
1999-04-12 |
2005-12-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
US6300069B1
(en)
|
1999-05-03 |
2001-10-09 |
Qiagen Gmbh |
Generation and amplification of nucleic acids from ribonucleic acids
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6066500A
(en)
|
1999-06-25 |
2000-05-23 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Beta catenin expression
|
US6271004B1
(en)
|
1999-06-25 |
2001-08-07 |
Display Systems Biotech A/S |
Method for improved reverse transcription at high temperatures
|
US6414135B1
(en)
|
1999-07-07 |
2002-07-02 |
Isis Pharmaceuticals, Inc. |
C3′-methylene hydrogen phosphonate monomers and related compounds
|
US20030092647A1
(en)
|
2001-08-08 |
2003-05-15 |
Crooke Rosanne M. |
Antisense modulation of cholesteryl ester transfer protein expression
|
US6147200A
(en)
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
US7264932B2
(en)
|
1999-09-24 |
2007-09-04 |
Applera Corporation |
Nuclease inhibitor cocktail
|
SK287400B6
(sk)
|
1999-09-25 |
2010-08-09 |
University Of Iowa Research Foundation |
Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
|
DE60029460T3
(de)
|
1999-09-27 |
2011-02-10 |
Coley Pharmaceutical Gmbh |
Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon
|
US6949520B1
(en)
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
US20020082227A1
(en)
|
1999-09-30 |
2002-06-27 |
Scott Henry |
Use of oligonucleotides for inhibition of complement activation
|
US6528262B1
(en)
|
1999-10-06 |
2003-03-04 |
Quark Biotech, Inc. |
Method for enrichment of natural antisense messenger RNA
|
GB9924285D0
(en)
|
1999-10-14 |
1999-12-15 |
Avecia Ltd |
Process
|
US20010055761A1
(en)
|
1999-10-29 |
2001-12-27 |
Agilent Technologies |
Small scale dna synthesis using polymeric solid support with functionalized regions
|
FR2800750B1
(fr)
*
|
1999-11-05 |
2003-01-31 |
Centre Nat Rech Scient |
Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
|
WO2001040515A1
(en)
|
1999-11-12 |
2001-06-07 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
US6322985B1
(en)
|
1999-12-27 |
2001-11-27 |
Technion Research And Development Foundation Ltd. |
Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing
|
US7501091B2
(en)
|
1999-12-30 |
2009-03-10 |
Smiths Detection Inc. |
Sensors with improved properties
|
WO2001050349A1
(en)
|
1999-12-30 |
2001-07-12 |
Rutgers, The State University Of New Jersey |
Electronic document customization and transformation utilizing user feedback
|
US6649750B1
(en)
|
2000-01-05 |
2003-11-18 |
Isis Pharmaceuticals, Inc. |
Process for the preparation of oligonucleotide compounds
|
US6159697A
(en)
|
2000-01-19 |
2000-12-12 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Smad7 expression
|
US7585847B2
(en)
|
2000-02-03 |
2009-09-08 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for the treatment of asthma and allergy
|
US6495677B1
(en)
|
2000-02-15 |
2002-12-17 |
Kanda S. Ramasamy |
Nucleoside compounds
|
GB0004889D0
(en)
|
2000-03-01 |
2000-04-19 |
Avecia Ltd |
Synthesis of oligonucleotides
|
EP1130091A3
(en)
|
2000-03-01 |
2001-11-14 |
Message Pharmaceuticals, Inc. |
Bacterial RNaseP Proteins and their use in identifying antibacterial compounds
|
WO2001070663A2
(en)
|
2000-03-17 |
2001-09-27 |
Corixa Corporation |
Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
|
DE10019756A1
(de)
|
2000-04-20 |
2001-10-25 |
Bayer Ag |
Verfahren zur Herstellung von superabsorbierenden Polymeren aus Polyacrylnitrilen
|
TR200402442T4
(tr)
|
2000-04-20 |
2004-12-21 |
F.Hoffmann-La Roche Ag |
Pirolidin ve piperidin türevleri ve bunların nörodejeneratif bozuklukların tedavisinde kullanımları
|
US20020013287A1
(en)
|
2000-05-09 |
2002-01-31 |
Reliable Biopharmaceuticals, Inc. St Louis Missouri |
Polymeric compounds useful as prodrugs
|
US6492171B2
(en)
|
2000-05-16 |
2002-12-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of TERT expression
|
US6815542B2
(en)
|
2000-06-16 |
2004-11-09 |
Ribapharm, Inc. |
Nucleoside compounds and uses thereof
|
US7238795B2
(en)
|
2000-08-03 |
2007-07-03 |
Roche Molecular Systems, Inc. |
Nucleic acid binding compounds containing pyrazolo[3,4-d]pyrimidine analogues of purin-2,6-diamine and their uses
|
US6725412B1
(en)
|
2000-08-15 |
2004-04-20 |
Dolby Laboratories Licensing Corporation |
Low latency data encoder
|
US6809195B1
(en)
|
2000-08-16 |
2004-10-26 |
Isis Pharmaceuticals, Inc. |
Process for the preparation of oligonucleotides
|
US6559279B1
(en)
|
2000-09-08 |
2003-05-06 |
Isis Pharmaceuticals, Inc. |
Process for preparing peptide derivatized oligomeric compounds
|
CA2419894A1
(en)
|
2000-09-15 |
2002-03-21 |
Coley Pharmaceutical Gmbh |
Process for high throughput screening of cpg-based immuno-agonist/antagonist
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
GB0024752D0
(en)
|
2000-10-10 |
2000-11-22 |
Univ Belfast |
Oxidative halogenation of aromatic compounds
|
AU4433702A
(en)
|
2000-10-18 |
2002-04-29 |
Smithkline Beecham Biolog |
Vaccines
|
US6372492B1
(en)
|
2000-10-30 |
2002-04-16 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of talin expression
|
US6682889B1
(en)
|
2000-11-08 |
2004-01-27 |
Becton, Dickinson And Company |
Amplification and detection of organisms of the Chlamydiaceae family
|
NL1016978C2
(nl)
|
2000-12-22 |
2002-06-25 |
Robert Jan Colenbrander |
Inrichting en werkwijze voor het verpakken en bereiden van voedsel en werkwijze voor het vervaardigen van een dergelijke inrichting.
|
GEP20053601B
(en)
|
2001-01-22 |
2005-08-10 |
Merck & Co Inc |
Nucleoside Derivatives as Inhibitors of RNA-Dependent RNA Viral Polymerase
|
US8008459B2
(en)
|
2001-01-25 |
2011-08-30 |
Evolva Sa |
Concatemers of differentially expressed multiple genes
|
WO2002059297A2
(en)
|
2001-01-25 |
2002-08-01 |
Evolva Biotech A/S |
A library of a collection of cells
|
AU2002224668B2
(en)
|
2001-01-26 |
2007-09-20 |
Commonwealth Scientific And Industrial Research Organisation |
Methods and means for producing efficient silencing construct using recombinational cloning
|
US20050277133A1
(en)
|
2001-05-18 |
2005-12-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US20030207804A1
(en)
|
2001-05-25 |
2003-11-06 |
Muthiah Manoharan |
Modified peptide nucleic acids
|
GB0113523D0
(en)
|
2001-06-04 |
2001-07-25 |
Torotrak Dev Ltd |
An Hydraulic control circuit for a continuosly variable transmission
|
US20030069410A1
(en)
|
2001-06-14 |
2003-04-10 |
Isis Pharmaceuticals, Inc. |
Methods for preparing oligonucleotides having chiral phosphorothioate linkages
|
US20050019915A1
(en)
|
2001-06-21 |
2005-01-27 |
Bennett C. Frank |
Antisense modulation of superoxide dismutase 1, soluble expression
|
SK15762003A3
(sk)
|
2001-06-29 |
2005-01-03 |
Chiron Corporation |
Kompozícia vakcíny HCV E1E2
|
CA2452458A1
(en)
|
2001-07-03 |
2003-01-16 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant chimeric oligonucleotides
|
US7205399B1
(en)
|
2001-07-06 |
2007-04-17 |
Sirna Therapeutics, Inc. |
Methods and reagents for oligonucleotide synthesis
|
US6440739B1
(en)
|
2001-07-17 |
2002-08-27 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of glioma-associated oncogene-2 expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US7888324B2
(en)
|
2001-08-01 |
2011-02-15 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US6455308B1
(en)
|
2001-08-01 |
2002-09-24 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of serum amyloid A4 expression
|
US7259150B2
(en)
|
2001-08-07 |
2007-08-21 |
Isis Pharmaceuticals, Inc. |
Modulation of apolipoprotein (a) expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
AU2002361468A1
(en)
|
2001-08-14 |
2003-03-18 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human S |
Method for rapid generation of mature dendritic cells
|
EP1418877A2
(en)
|
2001-08-24 |
2004-05-19 |
Massachusetts Institute Of Technology |
Reagents that facilitate the purification of compounds synthesized on a solid support
|
US7049122B2
(en)
|
2001-09-21 |
2006-05-23 |
Academia Sinica |
Mutant-type lipases and applications thereof
|
US6933288B2
(en)
|
2002-02-04 |
2005-08-23 |
Isis Pharmaceuticals, Inc. |
Pyranosyl cytosines: pharmaceutical formulations and methods
|
JP4348044B2
(ja)
|
2002-02-12 |
2009-10-21 |
株式会社キラルジェン |
立体規則性の高いジヌクレオシドホスホロチオエートの製造法
|
US20030159938A1
(en)
|
2002-02-15 |
2003-08-28 |
George Hradil |
Electroplating solution containing organic acid complexing agent
|
US20040149587A1
(en)
|
2002-02-15 |
2004-08-05 |
George Hradil |
Electroplating solution containing organic acid complexing agent
|
US8232383B2
(en)
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20050096284A1
(en)
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US7285658B2
(en)
|
2002-02-28 |
2007-10-23 |
Biota, Inc. |
Nucleotide mimics and their prodrugs
|
AU2003213628A1
(en)
|
2002-02-28 |
2003-09-16 |
Biota, Inc. |
Nucleoside 5'-monophosphate mimics and their prodrugs
|
US7288376B2
(en)
|
2002-03-22 |
2007-10-30 |
Council Of Scientific And Industrial Research |
Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis
|
US20040102394A1
(en)
|
2002-11-23 |
2004-05-27 |
Isis Pharmaceuticals Inc. |
Modulation of huntingtin interacting protein 2 expression
|
US7247621B2
(en)
|
2002-04-30 |
2007-07-24 |
Valeant Research & Development |
Antiviral phosphonate compounds and methods therefor
|
WO2003097662A1
(en)
|
2002-05-15 |
2003-11-27 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein b expression
|
WO2003099840A1
(en)
|
2002-05-24 |
2003-12-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
US20040014108A1
(en)
|
2002-05-24 |
2004-01-22 |
Eldrup Anne B. |
Oligonucleotides having modified nucleoside units
|
US7507808B2
(en)
|
2002-12-12 |
2009-03-24 |
Isis Pharmaceuticals, Inc. |
Modulation of endothelial lipase expression
|
AU2003248708A1
(en)
|
2002-06-17 |
2003-12-31 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
|
CN1662253A
(zh)
|
2002-06-20 |
2005-08-31 |
赛托斯生物技术公司 |
用作佐剂的包装的病毒样颗粒:制备方法与用途
|
WO2004003228A1
(en)
|
2002-07-01 |
2004-01-08 |
Unisearch Limited |
Genotyping method
|
EP2314690A1
(en)
|
2002-07-10 |
2011-04-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
RNA-interference by single-stranded RNA molecules
|
US20040023905A1
(en)
|
2002-07-31 |
2004-02-05 |
Isis Pharmaceuticals Inc. |
Antisense modulation of LAR expression
|
US20050042646A1
(en)
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
US20050255086A1
(en)
|
2002-08-05 |
2005-11-17 |
Davidson Beverly L |
Nucleic acid silencing of Huntington's Disease gene
|
US20080274989A1
(en)
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
WO2004014933A1
(en)
|
2002-08-07 |
2004-02-19 |
University Of Massachusetts |
Compositions for rna interference and methods of use thereof
|
WO2004014312A2
(en)
|
2002-08-08 |
2004-02-19 |
Sirna Therapeutics, Inc. |
Small-mer compositions and methods of use
|
GT200300176A
(es)
|
2002-08-19 |
2004-03-29 |
|
Acidos nucleicos inmunoestimuladores
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
US7414116B2
(en)
|
2002-08-23 |
2008-08-19 |
Illumina Cambridge Limited |
Labelled nucleotides
|
EA008940B1
(ru)
|
2002-09-13 |
2007-10-26 |
Репликор, Инк. |
Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
|
US7030230B2
(en)
|
2002-10-25 |
2006-04-18 |
Isis Pharmaceuticals, Inc. |
Process of purifying phosphoramidites
|
DE20216677U1
(de)
|
2002-10-29 |
2003-03-13 |
TRW Automotive Electronics & Components GmbH & Co.KG, 67677 Enkenbach-Alsenborn |
Luftausströmer mit Getränkehalter
|
PT2241325E
(pt)
|
2002-10-29 |
2012-04-12 |
Coley Pharm Gmbh |
Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
|
WO2004042029A2
(en)
|
2002-11-05 |
2004-05-21 |
Isis Pharmaceuticals, Inc. |
Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
|
AU2003291721A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
WO2004044141A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Conjugated oligomeric compounds and their use in gene modulation
|
EP1562971B1
(en)
|
2002-11-05 |
2014-02-12 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US7381527B2
(en)
|
2002-11-06 |
2008-06-03 |
Council Of Scientific And Industrial Research |
Method of detection of SP-A2 gene variants
|
US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
EP1569695B1
(en)
|
2002-11-13 |
2013-05-15 |
Genzyme Corporation |
Antisense modulation of apolipoprotein b expression
|
PT2284266E
(pt)
|
2002-11-14 |
2013-12-17 |
Thermo Fisher Scient Biosciences Inc |
Siarn contra tp53
|
AU2003225705A1
(en)
|
2003-03-07 |
2004-09-30 |
Ribapharm Inc. |
Cytidine analogs and methods of use
|
EP2239329A1
(en)
|
2003-03-07 |
2010-10-13 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
CA2524255C
(en)
|
2003-03-21 |
2014-02-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
GB0306657D0
(en)
|
2003-03-24 |
2003-04-30 |
Avecia Ltd |
Process and compounds
|
AU2004224762B2
(en)
|
2003-03-26 |
2009-12-24 |
Kuros Us Llc |
Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
|
US7537767B2
(en)
|
2003-03-26 |
2009-05-26 |
Cytis Biotechnology Ag |
Melan-A- carrier conjugates
|
ITRM20030149A1
(it)
|
2003-04-02 |
2004-10-03 |
Giuliani Spa |
Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US20090247488A1
(en)
|
2003-04-25 |
2009-10-01 |
Carina Cannizzaro |
Anti-inflammatory phosphonate compounds
|
US20050261237A1
(en)
|
2003-04-25 |
2005-11-24 |
Boojamra Constantine G |
Nucleoside phosphonate analogs
|
US7432261B2
(en)
|
2003-04-25 |
2008-10-07 |
Gilead Sciences, Inc. |
Anti-inflammatory phosphonate compounds
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
MXPA05011297A
(es)
|
2003-04-25 |
2006-05-25 |
Gilead Sciences Inc |
Analogos antivirales de fosfonato.
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
AU2004233989A1
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
CN101410120A
(zh)
|
2003-04-25 |
2009-04-15 |
吉里德科学公司 |
抗炎的膦酸酯化合物
|
WO2004096233A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Nucleoside phosphonate conjugates
|
US7045306B2
(en)
|
2003-04-28 |
2006-05-16 |
The General Hospital Corporation |
Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein
|
US7214491B2
(en)
|
2003-05-07 |
2007-05-08 |
E. I. Du Pont De Nemours And Company |
Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
|
WO2004101787A1
(ja)
|
2003-05-14 |
2004-11-25 |
Japan Science And Technology Agency |
ハンチンチン遺伝子の発現抑制
|
US7541344B2
(en)
|
2003-06-03 |
2009-06-02 |
Eli Lilly And Company |
Modulation of survivin expression
|
WO2005007672A2
(en)
|
2003-06-20 |
2005-01-27 |
Coley Pharmaceutical Gmbh |
Small molecule toll-like receptor (tlr) antagonists
|
EP1648914A4
(en)
|
2003-07-31 |
2009-12-16 |
Regulus Therapeutics Inc |
OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
|
JP2011088935A
(ja)
|
2003-08-08 |
2011-05-06 |
Chiralgen Ltd |
リン原子修飾ヌクレオチド類縁体の製造のための光学活性ヌクレオシド3’−ホスホロアミダイト
|
JP2005089441A
(ja)
|
2003-08-08 |
2005-04-07 |
Toudai Tlo Ltd |
立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
WO2005019237A1
(en)
|
2003-08-21 |
2005-03-03 |
Griffith University |
Novel sulfenamides
|
MXPA06001974A
(es)
|
2003-08-21 |
2006-05-31 |
Univ Griffith |
Nuevos oxidos de sulfenamida.
|
AU2004269026B2
(en)
|
2003-08-27 |
2010-02-25 |
Biota Scientific Management Pty Ltd |
Novel tricyclic nucleosides or nucleotides as therapeutic agents
|
ATE555118T1
(de)
|
2003-08-28 |
2012-05-15 |
Takeshi Imanishi |
Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
|
WO2005023828A1
(ja)
|
2003-09-02 |
2005-03-17 |
Takeshi Wada |
リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
|
JP4616175B2
(ja)
|
2003-09-02 |
2011-01-19 |
株式会社キラルジェン |
5’−ホスフィチル化モノマーおよびh−ホスホネートオリゴヌクレオチド誘導体の製造方法
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
KR101319388B1
(ko)
|
2003-09-09 |
2013-10-22 |
제론 코포레이션 |
텔로머라제 억제를 위한 변형 올리고뉴클레오티드
|
US20050074801A1
(en)
|
2003-09-09 |
2005-04-07 |
Monia Brett P. |
Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
|
EP1670518B1
(en)
|
2003-09-12 |
2014-05-21 |
University of Massachusetts |
Rna interference for the treatment of gain-of-function disorders
|
WO2008005562A2
(en)
|
2006-07-07 |
2008-01-10 |
University Of Massachusetts |
Rna silencing compositions and methods for the treatment of huntington's disease
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
AU2003304537A1
(en)
|
2003-10-16 |
2004-06-06 |
Form Puller Tool Co., Inc. |
Device for removing modular forms
|
SG123799A1
(en)
|
2003-10-30 |
2006-07-26 |
Coley Pharm Gmbh |
C-class oligonucleotide analogs with enchanced immunostimulatory potency
|
US20050239102A1
(en)
|
2003-10-31 |
2005-10-27 |
Verdine Gregory L |
Nucleic acid binding oligonucleotides
|
US7846436B2
(en)
|
2003-11-28 |
2010-12-07 |
Chemgenes Corporation |
Oligonucleotides and related compounds
|
WO2005063983A1
(en)
|
2003-12-29 |
2005-07-14 |
Galapagos Genomics N.V. |
Modulators of bone homeostasis identified in a high-throughput screen
|
JP4945129B2
(ja)
|
2004-01-27 |
2012-06-06 |
株式会社キラルジェン |
フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
US20050176045A1
(en)
|
2004-02-06 |
2005-08-11 |
Dharmacon, Inc. |
SNP discriminatory siRNA
|
EP1725250A2
(en)
|
2004-02-18 |
2006-11-29 |
Frutarom Ltd. |
Method for the preparation of peptide-oligonucleotide conjugates
|
JP3976742B2
(ja)
|
2004-02-27 |
2007-09-19 |
江守商事株式会社 |
インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
|
WO2005085272A1
(ja)
|
2004-03-05 |
2005-09-15 |
Takeshi Wada |
ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
JP4865544B2
(ja)
|
2004-03-25 |
2012-02-01 |
株式会社キラルジェン |
立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
EP2540734B1
(en)
|
2004-04-05 |
2016-03-30 |
Alnylam Pharmaceuticals, Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
TWI350168B
(en)
*
|
2004-05-07 |
2011-10-11 |
Incyte Corp |
Amido compounds and their use as pharmaceuticals
|
WO2005116268A2
(en)
|
2004-05-27 |
2005-12-08 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health |
Differential expression of molecules associated with acute stroke
|
US7759318B1
(en)
|
2004-05-28 |
2010-07-20 |
Isis Pharmaceuticals, Inc. |
Identification of novel pathways, genes and promoter motifs regulating adipogenesis
|
AU2005252662B2
(en)
|
2004-06-03 |
2011-08-18 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
EP3029142A1
(en)
|
2004-06-28 |
2016-06-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
EP2997980B1
(en)
|
2004-08-10 |
2017-12-20 |
Kastle Therapeutics, LLC |
Methods for modulating lipoprotein and cholesterol levels in humans
|
CN101048423B
(zh)
|
2004-08-26 |
2011-06-08 |
日本新药株式会社 |
亚磷酰胺化合物及低聚核糖核酸的制备方法
|
CA2578046A1
(en)
|
2004-09-07 |
2006-03-16 |
Archemix Corp. |
Aptamer medicinal chemistry
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US20090203132A1
(en)
|
2004-09-09 |
2009-08-13 |
Swayze Eric E |
Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
|
WO2006034348A2
(en)
|
2004-09-17 |
2006-03-30 |
Isis Pharmaceuticals, Inc. |
Enhanced antisense oligonucleotides
|
CA2582464A1
(en)
|
2004-10-13 |
2006-04-27 |
Sanjay Bhanot |
Antisense modulation of ptp1b expression
|
US7622451B2
(en)
|
2004-11-03 |
2009-11-24 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
AU2005301957B2
(en)
|
2004-11-03 |
2012-02-23 |
Department Of Health And Human Services |
Novobiocin analogues as anticancer agents
|
US8212012B2
(en)
|
2004-11-03 |
2012-07-03 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
US9120774B2
(en)
|
2004-11-03 |
2015-09-01 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
US8212011B2
(en)
|
2004-11-03 |
2012-07-03 |
University Of Kansas |
Novobiocin analogues
|
KR100721928B1
(ko)
|
2004-11-05 |
2007-05-28 |
주식회사 바이오씨에스 |
CpG 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
|
EP1657307A1
(en)
|
2004-11-16 |
2006-05-17 |
Immunotech S.A. |
Oligonucleotides that induce the secretion of GM-CSF
|
EP1819365B1
(en)
|
2004-12-09 |
2014-07-02 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
|
WO2006065751A2
(en)
|
2004-12-13 |
2006-06-22 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
WO2006066260A2
(en)
|
2004-12-17 |
2006-06-22 |
Thiosense, Inc. |
Compositions of and methods for producing phosphorus-chiral monomers and oligomers
|
US20070099851A1
(en)
|
2004-12-30 |
2007-05-03 |
Linn Gregory S |
Stable analogues of ribose-1-phosphate and methods for treating diabetes and other metabolic disorders
|
US20060183763A1
(en)
*
|
2004-12-31 |
2006-08-17 |
Pfizer Inc |
Novel pyrrolidyl derivatives of heteroaromatic compounds
|
CA2549423C
(en)
|
2005-01-28 |
2012-10-02 |
Hyung-Joo Kwon |
Oligonucleotides derived from mycobacterium for stimulating immune function, treating immune-related diseases, atopic dermatitis and/or protecting normal immune cell
|
CA2598992A1
(en)
|
2005-02-24 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory oligonucleotides
|
US8222257B2
(en)
|
2005-04-01 |
2012-07-17 |
The Regents Of The University Of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
ES2319332T3
(es)
|
2005-05-05 |
2009-05-06 |
Antisense Pharma Gmbh |
Uso terapeutico de oligonucleotidos antisentido tgf-beta 2'.
|
WO2006121960A2
(en)
|
2005-05-06 |
2006-11-16 |
Medtronic, Inc. |
Methods and sequences to suppress primate huntington gene expression
|
US7902352B2
(en)
|
2005-05-06 |
2011-03-08 |
Medtronic, Inc. |
Isolated nucleic acid duplex for reducing huntington gene expression
|
WO2007002390A2
(en)
|
2005-06-23 |
2007-01-04 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of smn2 splicing
|
US9133517B2
(en)
|
2005-06-28 |
2015-09-15 |
Medtronics, Inc. |
Methods and sequences to preferentially suppress expression of mutated huntingtin
|
ATE522626T1
(de)
|
2005-06-28 |
2011-09-15 |
Medtronic Inc |
Verfahren und nukleotid-sequenzen, die bevorzugt die expression eines mutierten huntingtin-genes unterdrücken
|
US20090162316A1
(en)
|
2005-07-05 |
2009-06-25 |
Harvard University |
Liver targeted conjugates
|
JP4984634B2
(ja)
|
2005-07-21 |
2012-07-25 |
ソニー株式会社 |
物理情報取得方法および物理情報取得装置
|
AU2006275632B2
(en)
|
2005-07-28 |
2011-11-03 |
Id-Fish Technology, Inc. |
Method for improving cell permeability to foreign particles
|
EP2338991B1
(en)
|
2005-08-29 |
2017-01-18 |
Regulus Therapeutics Inc. |
Methods for use in modulating MIR-122a
|
WO2007028065A2
(en)
|
2005-08-30 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
US20070077993A1
(en)
|
2005-09-30 |
2007-04-05 |
Midgley Timothy M |
Method and apparatus for collecting user game play data and crediting users in a gaming environment
|
ES2542989T3
(es)
|
2005-10-12 |
2015-08-13 |
Idera Pharmaceuticals, Inc. |
Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll
|
US9308252B2
(en)
|
2005-10-27 |
2016-04-12 |
Cook Biotech, Inc. |
Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
|
EP1942185A4
(en)
|
2005-10-28 |
2009-11-25 |
Tosoh Corp |
PROCESS FOR PREPARING CAROTINOIDY SYNTHETIZING MICROORGANISM AND METHOD FOR CAROTINOID PRODUCTION
|
AU2006305886C1
(en)
|
2005-10-28 |
2011-03-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of huntingtin gene
|
WO2007059041A2
(en)
|
2005-11-11 |
2007-05-24 |
Pfizer, Inc. |
Combinations and methods of using an immunomodulatory oligodeoxynucleotide
|
WO2007064291A1
(en)
|
2005-11-30 |
2007-06-07 |
Jyoti Chattopadhyaya |
Method and compounds for rna synthesis
|
ES2707787T3
(es)
|
2005-12-02 |
2019-04-05 |
Ionis Pharmaceuticals Inc |
Análogos antibacterianos de aminoglucósido 4,5-sustituidos que tienen sustituyentes múltiples
|
US8076303B2
(en)
|
2005-12-13 |
2011-12-13 |
Spring Bank Pharmaceuticals, Inc. |
Nucleotide and oligonucleotide prodrugs
|
EA015513B1
(ru)
*
|
2005-12-21 |
2011-08-30 |
Пфайзер Продактс Инк. |
Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
|
EP2422819B1
(en)
|
2006-01-26 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Compositions and their uses directed to Huntingtin
|
PL1984381T3
(pl)
|
2006-01-27 |
2011-03-31 |
Isis Pharmaceuticals Inc |
Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
|
PT1991678E
(pt)
|
2006-02-15 |
2015-11-25 |
Adiutide Pharmaceuticals Gmbh |
Composições e métodos para formulações de oligonucleótidos
|
JP4713514B2
(ja)
|
2006-02-20 |
2011-06-29 |
エフ.ホフマン−ラ ロシュ アーゲー |
改善された標識試薬
|
WO2007102499A1
(ja)
|
2006-03-06 |
2007-09-13 |
Japan Tobacco Inc. |
4-オキソキノリン化合物の製造方法
|
US8383660B2
(en)
*
|
2006-03-10 |
2013-02-26 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
EP2001871B1
(en)
|
2006-03-31 |
2014-07-16 |
Applied Biosystems, LLC |
Rhodamine-labeled oligonucleotides
|
US8088582B2
(en)
|
2006-04-06 |
2012-01-03 |
Ibis Biosciences, Inc. |
Compositions for the use in identification of fungi
|
KR101176697B1
(ko)
*
|
2006-04-20 |
2012-08-23 |
에프. 호프만-라 로슈 아게 |
케모카인 수용체의 다이아제판 유도체 조절자
|
US8206923B2
(en)
|
2006-04-24 |
2012-06-26 |
Elvira Garza Gonzalez |
Method for detection and multiple, simultaneous quantification of pathogens by means of real-time polymerase chain reaction
|
WO2007127219A2
(en)
|
2006-04-25 |
2007-11-08 |
Immune Disease Institute, Inc. |
Targeted delivery to leukocytes using protein carriers
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
EP2015758B1
(en)
|
2006-05-05 |
2014-04-02 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression apob
|
US8158598B2
(en)
|
2006-05-05 |
2012-04-17 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to PTPR alpha
|
US20090012120A1
(en)
|
2006-05-10 |
2009-01-08 |
Board Of Trustees Of Michigan State University |
Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines
|
US7547684B2
(en)
|
2006-05-11 |
2009-06-16 |
Isis Pharmaceuticals, Inc. |
5′-modified bicyclic nucleic acid analogs
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
CA2653939C
(en)
|
2006-05-31 |
2013-01-22 |
Toray Industries, Inc. |
Immunostimulatory oligonucleotides and use thereof in pharmaceuticals
|
US8097596B2
(en)
|
2006-06-30 |
2012-01-17 |
Lakewood-Amedex, Inc. |
Compositions and methods for the treatment of muscle wasting
|
US20090093425A1
(en)
|
2006-07-12 |
2009-04-09 |
The Regents Of The University Of California |
Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
|
AU2007275301A1
(en)
*
|
2006-07-20 |
2008-01-24 |
Amgen Inc. |
Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
|
GB0614947D0
(en)
|
2006-07-27 |
2006-09-06 |
Isis Innovation |
Epitope reduction therapy
|
US8101585B2
(en)
|
2006-08-04 |
2012-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of JNK proteins
|
AT504194B1
(de)
|
2006-09-07 |
2008-07-15 |
Oesterr Rotes Kreuz |
Bakteriennachweis
|
US8138330B2
(en)
|
2006-09-11 |
2012-03-20 |
Sigma-Aldrich Co. Llc |
Process for the synthesis of oligonucleotides
|
CN101517082B
(zh)
|
2006-09-27 |
2014-01-22 |
科勒制药有限责任公司 |
具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
|
US8535764B2
(en)
|
2006-10-18 |
2013-09-17 |
The Nanosteel Company, Inc. |
Protective coating for concrete delivery system components
|
WO2008051763A1
(en)
|
2006-10-23 |
2008-05-02 |
Irm Llc |
Cathepsin proteases inhibitors
|
WO2008139262A2
(en)
|
2006-10-26 |
2008-11-20 |
Coley Pharmaceutical Gmbh |
Oligoribonucleotides and uses thereof
|
FR2908414B1
(fr)
|
2006-11-13 |
2012-01-20 |
Centre Nat Rech Scient |
Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
|
CA2669917A1
(en)
*
|
2006-11-17 |
2008-05-22 |
Dawn M. George |
Aminopyrrolidines as chemokine receptor antagonists
|
KR20090103894A
(ko)
|
2006-11-27 |
2009-10-01 |
아이시스 파마수티컬즈 인코포레이티드 |
고콜레스테롤혈증을 치료하는 방법
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
EP2079305A4
(en)
|
2006-12-12 |
2010-01-27 |
Idera Pharmaceuticals Inc |
SYNTHETIC AGONISTS OF TLR9
|
UY30892A1
(es)
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
US20100190837A1
(en)
|
2007-02-15 |
2010-07-29 |
Isis Pharmaceuticals, Inc. |
5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
|
US9347061B2
(en)
|
2007-03-24 |
2016-05-24 |
Genzyme Corporation |
Administering antisense oligonucleotides complementary to human apolipoprotein B
|
US7960353B2
(en)
|
2007-05-10 |
2011-06-14 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
EP2158316B1
(en)
|
2007-05-11 |
2015-04-15 |
Adynxx, Inc. |
Gene expression and pain
|
WO2008143343A1
(ja)
|
2007-05-24 |
2008-11-27 |
Kyorin Pharmaceutical Co., Ltd. |
14位置換基に複素芳香環カルボン酸構造を有するムチリン誘導体
|
GB0710186D0
(en)
|
2007-05-29 |
2007-07-04 |
Texas Instr Denmark |
PWM loop with minimum allasing error property
|
US8278425B2
(en)
|
2007-05-30 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
UA98783C2
(en)
|
2007-06-05 |
2012-06-25 |
Нсаб, Филиал Аф Ньюросерч Свиден Аб, Свериге |
Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
|
US8278426B2
(en)
|
2007-06-08 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
WO2008151833A2
(en)
|
2007-06-13 |
2008-12-18 |
Hochschule Mannheim |
Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
|
ATE462787T1
(de)
|
2007-06-18 |
2010-04-15 |
Commissariat Energie Atomique |
Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington
|
GB0712494D0
(en)
|
2007-06-27 |
2007-08-08 |
Isis Innovation |
Substrate reduction therapy
|
WO2009006478A2
(en)
|
2007-07-05 |
2009-01-08 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
CN102921003B
(zh)
|
2007-07-09 |
2014-11-26 |
艾德拉药物股份有限公司 |
稳定化免疫调控性rna(simra)化合物
|
TWI413530B
(zh)
|
2007-07-20 |
2013-11-01 |
Kao Corp |
有機聚矽氧
|
US8008011B2
(en)
|
2007-07-31 |
2011-08-30 |
University Of Saskatchewan |
Genetic variation in pro-melanin-concentrating hormone gene affects carcass traits in cattle
|
WO2009017803A2
(en)
|
2007-08-02 |
2009-02-05 |
The Texas A & M University System |
Antisense microrna and uses therefor
|
CN101821412A
(zh)
|
2007-08-15 |
2010-09-01 |
艾德拉药物股份有限公司 |
Toll样受体调控剂
|
MX2010003606A
(es)
|
2007-10-01 |
2010-07-02 |
Isis Pharmaceuticals Inc |
Modulacion antisentido de la expresion del receptor del factor de crecimiento fibroblastico 4.
|
KR100886139B1
(ko)
|
2007-11-13 |
2009-02-27 |
주식회사 삼천리제약 |
올리고뉴클레오타이드의 제조방법
|
AR069869A1
(es)
|
2007-12-21 |
2010-02-24 |
Exelixis Inc |
Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
|
TWI340765B
(en)
|
2007-12-26 |
2011-04-21 |
Ind Tech Res Inst |
Oligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof
|
WO2009089659A1
(en)
|
2008-01-18 |
2009-07-23 |
Shanghai Targetdrug Co., Ltd. |
Pyrollidine-based compounds
|
JP2011515653A
(ja)
|
2008-02-04 |
2011-05-19 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
神経変性疾患の治療に有用な標的配列及びそれらの同定方法
|
JP2009190983A
(ja)
|
2008-02-12 |
2009-08-27 |
Tokyo Institute Of Technology |
オリゴヌクレオチド誘導体
|
WO2009117589A1
(en)
|
2008-03-21 |
2009-09-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
|
US20110269814A1
(en)
|
2008-03-26 |
2011-11-03 |
Alnylam Pharamaceuticals, Inc. |
2'-f modified rna interference agents
|
CN107753499A
(zh)
|
2008-04-03 |
2018-03-06 |
春堤制药公司 |
用于治疗病毒感染的化合物和方法
|
DE112009001327A5
(de)
|
2008-04-04 |
2011-03-31 |
Universität Hamburg |
Verfahren zur stereoselektiven Synthese von Phosphor-Verbindungen
|
EP2285819B1
(en)
|
2008-04-04 |
2013-10-16 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
US8679750B2
(en)
|
2008-05-09 |
2014-03-25 |
The University Of British Columbia |
Methods and compositions for the treatment of Huntington'S disease
|
WO2009135322A1
(en)
|
2008-05-09 |
2009-11-12 |
The Universtity Of British Columbia |
Methods and compositions for the treatment of huntington's disease
|
US8815817B2
(en)
|
2008-05-15 |
2014-08-26 |
Dynavax Technologies Corporation |
Long term disease modification using immunostimulatory oligonucleotides
|
WO2009143391A2
(en)
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc |
Methods for modulation expression of creb
|
US8541387B2
(en)
|
2008-05-22 |
2013-09-24 |
Isis Pharmaceuticals, Inc. |
Modulation of SMRT expression
|
US8541388B2
(en)
|
2008-05-22 |
2013-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating expression of RBP4
|
WO2009148605A2
(en)
|
2008-06-04 |
2009-12-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
CA2728559A1
(en)
|
2008-07-03 |
2010-01-07 |
Exelixis Inc. |
Cdk modulators
|
WO2010030849A1
(en)
|
2008-09-12 |
2010-03-18 |
University Of Louisville Research Foundation, Inc. |
Compositions and methods for treating cancer,inhibiting proliferation, and inducing cell death
|
US8163707B2
(en)
|
2008-09-15 |
2012-04-24 |
Enanta Pharmaceuticals, Inc. |
4′-allene-substituted nucleoside derivatives
|
WO2010039543A2
(en)
|
2008-09-23 |
2010-04-08 |
Traversa Therapeutics, Inc. |
Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
|
WO2010036696A1
(en)
|
2008-09-24 |
2010-04-01 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acid analogs
|
WO2010036698A1
(en)
|
2008-09-24 |
2010-04-01 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-l-bicyclic nucleosides
|
WO2010042636A2
(en)
|
2008-10-07 |
2010-04-15 |
President And Fellows Of Harvard College |
Telomerase inhibitors and methods of use thereof
|
WO2010048352A2
(en)
|
2008-10-22 |
2010-04-29 |
Quark Pharmaceuticals, Inc. |
Methods for treating eye disorders
|
AU2009308217B2
(en)
|
2008-10-24 |
2016-01-21 |
Ionis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
EP2358398A2
(en)
|
2008-10-24 |
2011-08-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
BRPI0923225A2
(pt)
|
2008-12-02 |
2016-10-04 |
Chiralgen Ltd |
metodo para sintese de acidos nucleicos modificados no atomo de fosforo
|
CN102307889A
(zh)
|
2008-12-23 |
2012-01-04 |
集润德斯股份公司 |
硫化剂及其用于寡核苷酸合成的用途
|
WO2010080953A1
(en)
|
2009-01-08 |
2010-07-15 |
Isis Pharmaceuticals, Inc. |
Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease
|
KR20100087540A
(ko)
|
2009-01-28 |
2010-08-05 |
삼성전자주식회사 |
잉크젯 기록용 잉크 조성물
|
WO2010091301A1
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and excipients
|
CA2752694A1
(en)
|
2009-02-10 |
2010-08-19 |
Idera Pharmaceuticals, Inc. |
Synthetic rna-based agonists of tlr7
|
JP5766617B2
(ja)
|
2009-02-20 |
2015-08-19 |
ユニバーシティ・オブ・カンザス |
修飾された糖部分を有するノボビオシン類似体
|
EP2403863B1
(en)
*
|
2009-03-02 |
2013-08-28 |
Alnylam Pharmaceuticals Inc. |
Nucleic acid chemical modifications
|
EP2408796B1
(en)
|
2009-03-16 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
|
DE112010001770B4
(de)
|
2009-03-16 |
2014-09-25 |
Nokia Corp. |
System mit einem steuermittel für eine richtantenne und vorrichtung, benutzerschnittstelle, verfahren und computerprogramm
|
US8653254B2
(en)
|
2009-03-31 |
2014-02-18 |
Takeda Pharmaceutical Company Limited |
Process for producing nucleoside
|
WO2010118263A1
(en)
|
2009-04-08 |
2010-10-14 |
University Of Massachusetts |
Single-nucleotide polymorphism (snp) targeting therapies for the treatment of huntington's disease
|
US20120156138A1
(en)
|
2009-04-14 |
2012-06-21 |
Smith Larry J |
Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming
|
WO2010129853A2
(en)
|
2009-05-07 |
2010-11-11 |
The Regents Of The University Of California |
TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS USING MODIFIED dsRNA BINDING DOMAINS
|
AU2010256836A1
(en)
|
2009-06-01 |
2012-01-19 |
The Regents Of The University Of California |
Nucleic acid delivery compositions and methods of use thereof
|
CN105131051B
(zh)
|
2009-06-05 |
2020-07-10 |
传染性疾病研究院 |
合成的吡喃葡萄糖脂佐剂
|
NZ597071A
(en)
|
2009-06-17 |
2014-05-30 |
Isis Pharmaceuticals Inc |
Compositions and methods for modulation of smn2 splicing in a subject
|
JP5670097B2
(ja)
|
2009-06-19 |
2015-02-18 |
花王株式会社 |
二層分離型毛髪化粧料
|
JPWO2010150789A1
(ja)
|
2009-06-23 |
2012-12-10 |
武田薬品工業株式会社 |
核酸の合成法
|
RU2612521C2
(ru)
|
2009-07-06 |
2017-03-09 |
Онтории, Инк. |
Новые пролекарства нуклеиновых кислот и способы их применения
|
US8329024B2
(en)
|
2009-07-06 |
2012-12-11 |
Ada Technologies, Inc. |
Electrochemical device and method for long-term measurement of hypohalites
|
WO2011005860A2
(en)
|
2009-07-07 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
5' phosphate mimics
|
WO2011005942A2
(en)
|
2009-07-08 |
2011-01-13 |
Idera Pharmaceuticals, Inc. |
Oligonucleotide-based compounds as inhibitors of toll-like receptors
|
WO2011010706A1
(ja)
|
2009-07-23 |
2011-01-27 |
武田薬品工業株式会社 |
Fgf21シスエレメント結合物質
|
WO2011015572A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
WO2011015573A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
UA107360C2
(en)
|
2009-08-05 |
2014-12-25 |
Biogen Idec Inc |
Bicyclic aryl sphingosine 1-phosphate analogs
|
EP2462153B1
(en)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
US8927553B2
(en)
|
2009-08-10 |
2015-01-06 |
Daljit Singh Dhanoa |
Deuterium-enriched alkyl sulfonamides and uses thereof
|
RU2751847C9
(ru)
|
2009-09-11 |
2021-08-20 |
Ионис Фармасьютикалз, Инк. |
Модуляция экспрессии гентингтина
|
JP5878758B2
(ja)
|
2009-09-16 |
2016-03-08 |
株式会社Wave Life Sciences Japan |
Rna及びその誘導体合成のための新規保護基
|
EP2480667A4
(en)
|
2009-09-25 |
2013-07-03 |
Isis Pharmaceuticals Inc |
MODULATION OF TTC39 EXPRESSION FOR HDL INCREASE
|
CA2776028C
(en)
|
2009-10-15 |
2015-12-01 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine compounds
|
TWI475051B
(zh)
|
2009-11-18 |
2015-03-01 |
Kao Corp |
Organic polysiloxane
|
JP5809408B2
(ja)
|
2009-11-25 |
2015-11-10 |
花王株式会社 |
毛髪化粧料
|
EP2512246B1
(en)
*
|
2009-12-17 |
2015-09-30 |
Merck Sharp & Dohme Corp. |
Aminopyrimidines as syk inhibitors
|
CN102812361A
(zh)
|
2009-12-28 |
2012-12-05 |
阿茨拉实验室有限公司 |
诊断凝胶组合物、制造诊断凝胶组合物的方法
|
CN111700901A
(zh)
|
2010-01-08 |
2020-09-25 |
Ionis制药公司 |
血管生成素样3表达的调节
|
US8750507B2
(en)
|
2010-01-25 |
2014-06-10 |
Cisco Technology, Inc. |
Dynamic group creation for managed key servers
|
EP3628750A1
(en)
|
2010-02-08 |
2020-04-01 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
CA2789005A1
(en)
|
2010-02-08 |
2011-08-11 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
PT2534149E
(pt)
|
2010-02-10 |
2014-12-23 |
Glaxosmithkline Llc |
Maleato de 6-amino-2-{[(1s)-1-metilbutil]oxi}-9-[5-(1- piperidinil)pentil]-7,9-di-hidro-8h-purin-8-ona
|
CN102918052A
(zh)
*
|
2010-03-05 |
2013-02-06 |
国立大学法人东京大学 |
硫代磷酸核糖核苷的制造方法
|
WO2011127175A1
(en)
|
2010-04-06 |
2011-10-13 |
Isis Pharmaceuticals, Inc. |
Modulation of cd130 (gp130) expression
|
WO2011127307A1
(en)
|
2010-04-07 |
2011-10-13 |
Isis Pharmaceuticals, Inc. |
Modulation of cetp expression
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
JP6005628B2
(ja)
|
2010-04-28 |
2016-10-12 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
|
US9127033B2
(en)
|
2010-04-28 |
2015-09-08 |
Isis Pharmaceuticals, Inc. |
5′ modified nucleosides and oligomeric compounds prepared therefrom
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
US8906607B2
(en)
|
2010-04-30 |
2014-12-09 |
Cellectis |
Method for modulating double-strand break-induced homologous recombination
|
GB201008902D0
(en)
|
2010-05-27 |
2010-07-14 |
Imp Innovations Ltd |
Membrane enhanced polymer sythesis
|
CN103221549A
(zh)
|
2010-08-31 |
2013-07-24 |
默沙东公司 |
用于递送寡核苷酸的新型简单化学实体和方法
|
US10428019B2
(en)
|
2010-09-24 |
2019-10-01 |
Wave Life Sciences Ltd. |
Chiral auxiliaries
|
CN103080314B
(zh)
|
2010-09-30 |
2016-04-13 |
Lsip基金运营联合公司 |
显性突变基因表达抑制剂
|
KR101381048B1
(ko)
|
2010-10-20 |
2014-04-14 |
씨제이제일제당 (주) |
O-포스포세린 생산 균주 및 이로부터 생산된 o-포스포세린으로부터 l-시스테인 또는 이의 유도체의 생산방법
|
EP2632472B1
(en)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
AU2011325956B2
(en)
|
2010-11-12 |
2016-07-14 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
WO2012073857A1
(ja)
|
2010-11-30 |
2012-06-07 |
株式会社キラルジェン |
2'-o-修飾rna
|
WO2012092367A1
(en)
|
2010-12-28 |
2012-07-05 |
University Of Rochester |
Nucleic acid binding compounds, methods of making, and use thereof
|
WO2012109395A1
(en)
|
2011-02-08 |
2012-08-16 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
WO2012109667A1
(en)
|
2011-02-12 |
2012-08-16 |
University Of Iowa Research Foundation |
Therapeutic compounds
|
WO2012151324A1
(en)
|
2011-05-02 |
2012-11-08 |
Isis Pharmaceuticals, Inc. |
Antisense compounds targeting genes associated with usher syndrome
|
FR2975600B1
(fr)
|
2011-05-24 |
2013-07-05 |
Assist Publ Hopitaux De Paris |
Agents pour le traitement de tumeurs
|
WO2013013068A2
(en)
|
2011-07-19 |
2013-01-24 |
University Of Idaho |
Embodiments of a probe and method for targeting nucleic acids
|
CN107365339A
(zh)
|
2011-07-19 |
2017-11-21 |
波涛生命科学有限公司 |
合成官能化核酸的方法
|
WO2013022966A1
(en)
|
2011-08-11 |
2013-02-14 |
Isis Pharmaceuticals, Inc. |
Linkage modified gapped oligomeric compounds and uses thereof
|
EP2751269B1
(en)
|
2011-08-29 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
US20140080896A1
(en)
|
2011-08-30 |
2014-03-20 |
The Regents Of The University Of California |
Identification of small molecules that facilitate therapeutic exon skipping
|
EP2751284B1
(en)
|
2011-08-31 |
2017-01-11 |
The University Of Manchester |
Method for diagnosing a neurodegenerative disease.
|
WO2013036833A1
(en)
|
2011-09-09 |
2013-03-14 |
Mayo Foundation For Medical Education And Research |
Detecting frontotemporal dementia and amyotrophic lateral sclerosis
|
EP2785729B1
(en)
|
2011-11-30 |
2020-11-04 |
Sarepta Therapeutics, Inc. |
Oligonucleotides for treating expanded repeat diseases
|
DK2790736T3
(da)
|
2011-12-12 |
2018-05-07 |
Oncoimmunin Inc |
In vivo levering af oligonukleotider
|
ES2707232T3
(es)
|
2011-12-16 |
2019-04-03 |
Univ Nat Corp Tokyo Medical & Dental |
Acido nucleico bicatenario quimérico
|
CN102675386B
(zh)
|
2011-12-24 |
2014-07-02 |
河南科技大学 |
一种龙胆苦苷分离提纯方法
|
US8957042B2
(en)
|
2012-03-07 |
2015-02-17 |
The Texas A&M University System |
Cancer treatment targeting non-coding RNA overexpression
|
JP6242378B2
(ja)
|
2012-03-13 |
2017-12-06 |
ギリアード サイエンシーズ, インコーポレイテッド |
抗ウイルス処置のための2’−置換カルバヌクレオシド類似体
|
KR20130114435A
(ko)
|
2012-04-09 |
2013-10-17 |
삼성전자주식회사 |
다수의 전극을 갖는 생분자 검출 장치
|
SI2841578T1
(sl)
|
2012-04-23 |
2017-12-29 |
Biomarin Technologies B.V. |
Rna modulirajoči oligonukleotidi z izboljšanimi karakteristikami za zdravljenje nevromuskularnih motenj
|
AU2013266393B2
(en)
|
2012-05-22 |
2017-09-28 |
Idenix Pharmaceuticals Llc |
D-amino acid compounds for liver disease
|
DK2857412T3
(da)
|
2012-05-30 |
2017-04-03 |
Hokkaido System Science Co Ltd |
Fremgangsmåde til oligonukleotidsyntese under anvendelse af højopløselig væskefasebærer
|
EP2872485B1
(en)
|
2012-07-13 |
2020-12-16 |
Wave Life Sciences Ltd. |
Asymmetric auxiliary group
|
PL2872147T3
(pl)
|
2012-07-13 |
2023-09-25 |
Wave Life Sciences Ltd. |
Sposób wytwarzania chiralnych oligonukleotydów
|
JP6246121B2
(ja)
|
2012-07-13 |
2017-12-13 |
株式会社新日本科学 |
キラル核酸アジュバント
|
AU2013299717B2
(en)
|
2012-08-06 |
2018-06-28 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugated RNA agents and process for their preparation
|
EP2885312A4
(en)
|
2012-08-15 |
2016-01-20 |
Isis Pharmaceuticals Inc |
PROCESS FOR THE PREPARATION OF OLIGOMERIC COMPOUNDS USING MODIFIED STREAMING PROTOCOLS
|
CA2887884A1
(en)
|
2012-10-12 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
JP6570447B2
(ja)
|
2012-10-15 |
2019-09-04 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
C9orf72発現を調節するための組成物
|
FI2906696T4
(fi)
|
2012-10-15 |
2023-03-18 |
|
Menetelmiä c9orf72:n ilmentymisen moduloimiseksi
|
WO2014062736A1
(en)
|
2012-10-15 |
2014-04-24 |
Isis Pharmaceuticals, Inc. |
Methods for monitoring c9orf72 expression
|
EP2725029A1
(en)
|
2012-10-29 |
2014-04-30 |
Laboratoire Biodim |
New antibacterial compounds and biological applications thereof
|
CN104884462A
(zh)
|
2012-10-29 |
2015-09-02 |
共晶制药股份有限公司 |
用于治疗病毒感染和癌症的嘧啶核苷及其单磷酸酯前药
|
US9725474B2
(en)
|
2012-10-31 |
2017-08-08 |
Takeda Pharmaceutical Company Limited |
Modified nucleic acid
|
BR112015010116A2
(pt)
|
2012-11-15 |
2017-08-22 |
Roche Innovation Ct Copenhagen As |
COMPOSTOS CONJUGADOS ANTI-SENTIDO ANTI-ApoB
|
WO2014080004A1
(en)
|
2012-11-26 |
2014-05-30 |
Santaris Pharma A/S |
Compositions and methods for modulation of fgfr3 expression
|
US9211300B2
(en)
|
2012-12-19 |
2015-12-15 |
Idenix Pharmaceuticals Llc |
4′-fluoro nucleosides for the treatment of HCV
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
EP2951305B1
(en)
|
2013-01-30 |
2018-08-15 |
F.Hoffmann-La Roche Ag |
Lna oligonucleotide carbohydrate conjugates
|
EP3778618A1
(en)
|
2013-02-04 |
2021-02-17 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
JP6613143B2
(ja)
|
2013-02-22 |
2019-11-27 |
サーナ・セラピューティクス・インコーポレイテッド |
2’ヌクレオシド間結合を含有する低分子干渉核酸(siNA)分子
|
WO2014132671A1
(en)
|
2013-03-01 |
2014-09-04 |
National University Corporation Tokyo Medical And Dental University |
Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
|
CA2907750A1
(en)
|
2013-03-28 |
2014-10-02 |
Syngenta Participations Ag |
Methods of controlling neonicotinoid resistant pests
|
EP2978317A1
(en)
|
2013-03-28 |
2016-02-03 |
Syngenta Participations AG |
Methods of controlling neonicotinoid resistant pests
|
MX2015015239A
(es)
|
2013-05-01 |
2016-10-03 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos.
|
JP2016520310A
(ja)
|
2013-05-24 |
2016-07-14 |
ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S |
B細胞cll/リンパ腫11a(bcl11a)のオリゴヌクレオチドモデュレーター及びその使用
|
WO2014189142A1
(ja)
|
2013-05-24 |
2014-11-27 |
味の素株式会社 |
モルフォリノオリゴヌクレオチドの製造方法
|
EP3004347B1
(en)
|
2013-05-30 |
2018-09-26 |
National University Corporation Tokyo Medical and Dental University |
Double-stranded agents for delivering therapeutic oligonucleotides
|
AU2014282666A1
(en)
|
2013-06-16 |
2016-01-07 |
National University Corporation Tokyo Medical And Dental University |
Double-stranded antisense nucleic acid with exon-skipping effect
|
WO2014205451A2
(en)
|
2013-06-21 |
2014-12-24 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
RS59986B1
(sr)
|
2013-06-27 |
2020-03-31 |
Roche Innovation Ct Copenhagen As |
Antisens oligomeri i konjugati koji ciljno deluju na pcsk9
|
TW202246503A
(zh)
|
2013-07-19 |
2022-12-01 |
美商百健Ma公司 |
用於調節τ蛋白表現之組合物
|
ES2750608T3
(es)
|
2013-07-25 |
2020-03-26 |
Exicure Inc |
Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
|
US10435430B2
(en)
|
2013-07-31 |
2019-10-08 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
JP2016534127A
(ja)
|
2013-09-06 |
2016-11-04 |
シンジェンタ パーティシペーションズ アーゲー |
殺虫性化合物
|
US10385088B2
(en)
|
2013-10-02 |
2019-08-20 |
Modernatx, Inc. |
Polynucleotide molecules and uses thereof
|
CN105980401A
(zh)
|
2013-10-03 |
2016-09-28 |
现代治疗公司 |
编码低密度脂蛋白受体的多核苷酸
|
US9988627B2
(en)
|
2013-10-04 |
2018-06-05 |
Novartis Ag |
Formats for organic compounds for use in RNA interference
|
MX2016004651A
(es)
|
2013-10-11 |
2016-08-05 |
Ionis Pharmaceuticals Inc |
Composiciones para modular la expresion de c9orf72.
|
US20160230172A1
(en)
|
2013-10-14 |
2016-08-11 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
US20160237432A1
(en)
|
2013-10-14 |
2016-08-18 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating expression of c9orf72 antisense transcript
|
BR112016010175A2
(pt)
|
2013-11-11 |
2017-10-03 |
Sangamo Biosciences Inc |
Repressor genético, seus usos, e composição farmacêutica
|
CA2928349A1
(en)
|
2013-11-14 |
2015-05-21 |
Roche Innovation Center Copenhagen A/S |
Apob antisense conjugate compounds
|
EP3053585A1
(en)
|
2013-12-13 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
WO2015108047A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
EP3095460A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
JP6382344B2
(ja)
|
2014-01-16 |
2018-08-29 |
ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. |
キラルデザイン
|
DK3119797T3
(da)
|
2014-03-18 |
2021-03-15 |
Univ Massachusetts |
Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
|
DK3137476T3
(da)
|
2014-04-28 |
2019-11-18 |
Ionis Pharmaceuticals Inc |
Linker-modificerede oligomerforbindelser
|
CA2946003A1
(en)
|
2014-05-01 |
2015-11-05 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating angiopoietin-like 3 expression
|
WO2015171932A1
(en)
|
2014-05-08 |
2015-11-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
CN107075514A
(zh)
|
2014-05-20 |
2017-08-18 |
衣阿华大学研究基金会 |
亨廷顿氏病的治疗化合物
|
US20160017327A1
(en)
|
2014-07-11 |
2016-01-21 |
The Johns Hopkins University |
Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity
|
AU2015289583A1
(en)
|
2014-07-16 |
2017-02-02 |
Modernatx, Inc. |
Chimeric polynucleotides
|
EP2982758A1
(en)
|
2014-08-04 |
2016-02-10 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Genome editing for the treatment of huntington's disease
|
AU2015300046B2
(en)
|
2014-08-07 |
2019-05-09 |
Takeda Pharmaceutical Company Limited |
Cationic lipid
|
WO2016024205A1
(en)
|
2014-08-15 |
2016-02-18 |
Pfizer Inc. |
Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
|
WO2016027168A2
(en)
|
2014-08-20 |
2016-02-25 |
Lifesplice Pharma Llc |
Splice modulating oligonucleotides and methods of use thereof
|
WO2016037191A1
(en)
|
2014-09-05 |
2016-03-10 |
Health Research, Inc. |
Use of huntingtin-derived plasmids and peptides for active immunization as a huntington's disease (hd) therapeutic
|
US20180016575A1
(en)
|
2014-11-19 |
2018-01-18 |
Roche Innovation Center Copenhagen A/S |
LNA Gapmer Oligonucleotides Comprising Chiral Phosphorothioate Linkages
|
US10815481B2
(en)
|
2014-12-16 |
2020-10-27 |
Roche Innovation Center Copenhagen A/S |
Chiral library screen
|
KR102636633B1
(ko)
|
2014-12-24 |
2024-02-13 |
유니큐어 아이피 비.브이. |
헌팅턴 유전자 억제를 유도하는 RNAi
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
EP3954993A1
(en)
|
2015-02-04 |
2022-02-16 |
Bristol-Myers Squibb Company |
Methods of selecting therapeutic molecules
|
DK3253875T3
(da)
|
2015-02-04 |
2020-04-14 |
H Hoffmann La Roche Ag |
Tau-antisense-oligomerer og anvendelser deraf
|
EP3253871A1
(en)
|
2015-02-04 |
2017-12-13 |
Bristol-Myers Squibb Company |
Lna oligonucleotides with alternating flanks
|
MA40819B1
(fr)
|
2015-02-10 |
2020-04-30 |
Genzyme Corp |
Variant d'arni
|
WO2016130806A2
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
EP3262174A4
(en)
|
2015-02-23 |
2018-10-17 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing antisense activity
|
WO2016141236A1
(en)
|
2015-03-03 |
2016-09-09 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating mecp2 expression
|
WO2016145142A1
(en)
|
2015-03-10 |
2016-09-15 |
Emory University |
Nucleotide and nucleoside therapeutics compositions and uses related thereto
|
WO2016154096A1
(en)
|
2015-03-20 |
2016-09-29 |
Ionis Pharmaceuticals, Inc. |
Modulation of smggds expression
|
US9809817B2
(en)
|
2015-04-03 |
2017-11-07 |
University Of Massachusetts |
Oligonucleotide compounds for targeting huntingtin mRNA
|
WO2016164896A2
(en)
|
2015-04-10 |
2016-10-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of smn expression
|
CN113265404A
(zh)
|
2015-04-16 |
2021-08-17 |
Ionis制药公司 |
用于调节c9orf72表达的组合物
|
US10407678B2
(en)
|
2015-04-16 |
2019-09-10 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
US11414657B2
(en)
|
2015-06-29 |
2022-08-16 |
Ionis Pharmaceuticals, Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
DK3320094T3
(da)
|
2015-07-10 |
2022-05-23 |
Ionis Pharmaceuticals Inc |
Modulatorer af diacyglycerol-acyltransferase 2 (dgat2)
|
EP3324980B1
(en)
|
2015-07-17 |
2021-11-10 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
TW201718620A
(zh)
|
2015-07-27 |
2017-06-01 |
阿尼拉製藥公司 |
黃嘌呤脫氫酶(XDH)iRNA組成物及其使用方法
|
SG10201912341SA
(en)
|
2015-07-31 |
2020-02-27 |
Alnylam Pharmaceuticals Inc |
TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES
|
KR20180043819A
(ko)
|
2015-08-24 |
2018-04-30 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
Lna-g 방법
|
EP3340994A1
(en)
|
2015-08-25 |
2018-07-04 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
|
CN108368507B
(zh)
|
2015-09-02 |
2022-03-22 |
阿尔尼拉姆医药品有限公司 |
程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
|
WO2017059411A1
(en)
|
2015-10-01 |
2017-04-06 |
Memorial Sloan-Kettering Cancer Center |
Inhibitors of menaquinone biosynthesis
|
US10874686B2
(en)
|
2015-10-01 |
2020-12-29 |
Memorial Sloan-Kettering Cancer Center |
Anthranilyl-adenosinemonosulfamate analogs and uses thereof
|
KR20180073584A
(ko)
|
2015-10-02 |
2018-07-02 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
올리고뉴클레오타이드 접합 방법
|
IL258230B
(en)
|
2015-10-09 |
2022-09-01 |
Wave Life Sciences Ltd |
Oligonucleotide preparations and methods thereof
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
EP3394258B1
(en)
|
2015-10-22 |
2021-09-22 |
Roche Innovation Center Copenhagen A/S |
In vitro toxicity screening assay
|
WO2017079291A1
(en)
|
2015-11-02 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating c90rf72
|
PE20181157A1
(es)
|
2015-11-12 |
2018-07-19 |
Hoffmann La Roche |
Oligonucleotidos para inducir la expresion paterna de ube3a
|
JP7286320B2
(ja)
|
2016-03-13 |
2023-06-05 |
ウェイブ ライフ サイエンシズ リミテッド |
ホスホラミダイト及びオリゴヌクレオチド合成のための組成物並びに方法
|
PE20230157A1
(es)
|
2016-03-14 |
2023-02-01 |
Hoffmann La Roche |
Oligonucleotidos para reducir la expresion de pd-l1
|
KR102372122B1
(ko)
|
2016-03-18 |
2022-03-07 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
아실-보호된 l-lna-구아노신 단량체
|
US11963972B2
(en)
|
2016-03-23 |
2024-04-23 |
Emory University |
Antiviral agents and nucleoside analogs for treatment of Zika virus
|
WO2017180835A1
(en)
|
2016-04-13 |
2017-10-19 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing c9orf72 expression
|
US11248019B2
(en)
|
2016-04-14 |
2022-02-15 |
Hoffmann-La Roche Inc. |
Trityl-mono-GalNAc compounds and their use
|
MA45290A
(fr)
|
2016-05-04 |
2019-03-13 |
Wave Life Sciences Ltd |
Procédés et compositions d'agents biologiquement actifs
|
US11261209B2
(en)
|
2016-05-12 |
2022-03-01 |
Roche Innovation Center Copenhagen A/S |
Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
|
EP3455354B1
(en)
|
2016-05-13 |
2023-07-12 |
Roche Diagnostics GmbH |
Protein-based sample collection matrices and devices
|
US10882884B2
(en)
|
2016-05-18 |
2021-01-05 |
Eth Zurich |
Stereoselective synthesis of phosphorothioate oligoribonucleotides
|
WO2017210647A1
(en)
|
2016-06-03 |
2017-12-07 |
Wave Life Sciences Ltd. |
Oligonucleotides, compositions and methods thereof
|
DK3473270T5
(da)
|
2016-06-20 |
2024-09-09 |
Genahead Bio Inc |
Konjugat af antistof-lægemiddel
|
US20190264267A1
(en)
|
2016-07-25 |
2019-08-29 |
Wave Life Sciences Ltd. |
Phasing
|
CN110088113A
(zh)
|
2016-11-23 |
2019-08-02 |
波涛生命科学有限公司 |
用于亚磷酰胺和寡核苷酸合成的组合物和方法
|